Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

Dartmouth Health

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Lung Cancer

Treatments: Biological: lepirudin

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00003726

D9815

DMS-9815 (Other Identifier)

P30CA023108 (U.S. NIH Grant/Contract)

NCI-V98-1512 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.

PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small cell lung cancer.

Full description

OBJECTIVES: I. Determine the dose, safety, and antitumor response rate of lepirudin in patients with recurrent or extensive stage small cell lung cancer previously treated with chemotherapy.

OUTLINE: This is a dose escalation (in individual patients) study. Patients receive dose escalated lepirudin subcutaneously once or twice a day for 3-4 days. Dose escalation continues in each patient until aPTT prolongation occurs or the maximum dose level is reached. The patient then continues treatment on the maximum tolerated dose. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 18-24 months.

Enrollment: 1 patient

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

1. Pathologically confirmed recurrent or extensive stage small cell lung cancer.
2. Received at least one prior chemotherapy regimen
3. Measurable or evaluable disease that has not been irradiated
4. No pleural effusions, bone metastases, brain metastases, elevated serum enzymes, or radionuclide scans as the sole indicator lesion
5. Brain metastases allowed if patients received cranial irradiation and have no clinical evidence of brain metastases

PATIENT CHARACTERISTICS:

1. Age: Not specified
2. Performance status: Karnofsky 60-100%
3. Life expectancy: Not specified
4. Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
5. Hepatic: Bilirubin no greater than 2.0 mg/dL PT and aPTT normal
6. Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min
7. Cardiovascular: No unstable heart rhythm No unstable angina No clinical evidence of congestive heart failure No prior cerebrovascular accident or stroke No uncontrolled or severe hypertension
8. Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
9. At least 6 weeks since any signs or symptoms of bleeding No history of bleeding disorder
10. No bacterial endocarditis or other active infection

PRIOR CONCURRENT THERAPY:

1. Biologic therapy: Not specified
2. Chemotherapy: At least 3 weeks since prior chemotherapy
3. Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy
4. Surgery: At least 6 weeks since major surgery, trauma, or needle biopsy of any organ
5. Other: No concurrent anticoagulant or platelet inhibitor therapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Lepirudin

Experimental group

Description:

Dose level 1: 10 mg once daily -\> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -\> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -\> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -\> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -\> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -\> (total dose, 50 mg/d)

Treatment:

Biological: lepirudin